Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding and control leaking during surgery and trauma care. The company’s innovative self-assembling peptide technology platform has been shown to make surgery and interventional care faster and safer for patients. Arch’s flagship development stage product candidate, the AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company’s website at www.archtherapeutics.com.